慢性アムロディピンの治療は,心不全の発症時に行われます
F G Spinale1, R Mukherjee, R S Krombach
1Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, USA.
Circulation
|October 20, 1998
まとめ
アムロジピン治療は,心不全の豚の心臓機能を改善しました. この研究では,アムロディピンが血動力学,神経ホルモン,心筋梗塞性心不全 (CHF) の心筋収縮性に有益であることを示しています.
科学分野:
- 心血管生理学 心血管の生理学
- 薬理学 薬理学とは
背景:
- 閉塞性心不全 (CHF) は,左心室 (LV) ポンプ機能の障害と血液動力学的変化によって特徴付けられます.
- 神経ホルモンの調節不全と地域血流の減少は,CHFの重要な特徴です.
- これらのパラメータに対する治療介入の影響を理解することは,CHFの管理に極めて重要です.
研究 の 目的:
- 慢性アムロディピンの治療が,豚のモデルで,LVポンプの機能,全身の血液動力学,および神経ホルモン状態に与える影響を調査する.
- 慢性心筋梗塞における休息と運動中の地域血流分布に対するアムロディピンの影響を評価する.
- 乳腺筋細胞の収縮機能に対するアムロディピンのインビトロ効果を調べる.
主な方法:
- 慢性的なペースインダクト性心不全 (CHF) は,3週間にわたって16匹の豚で確立されました.
- 豚はCHFとAMLODIPINE治療群 (それぞれn=8) とのCHFに分けられた.
- 測定対象は,LV脳卒中の体積,全身および肺血管抵抗,心筋血流量,血のノルエピネフリンおよびエンドセリン濃度,およびLV筋細胞収縮率でした.
主要な成果:
- CHFのブタは,運動中に減少したLV脳卒中容量,増加した血管抵抗,および減少した心筋血流を示した.
- アムロジピン治療は,LV脳卒中容量を正常化し,血管抵抗を減らし,心筋血流を改善しました.
- プラズマのノレピネフリンとエンドセリンのレベルは,アムロディピンによって低下し,LVミオサイトの縮小速度が増加しました.
結論:
- 慢性アムロディピン治療は,発症中のCHFモデルで好ましい血液動力学的効果を示した.
- アムロディピンは,神経ホルモンの状態に肯定的な影響を及ぼし,CHFにおける心筋細胞の収縮性を改善しました.
- これらの発見は,アムロディピンが,閉塞性心不全の管理のための有益な治療法であることを示唆しています.
関連する概念動画
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.